Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus

NCT05440422 is registered in ClinicalTrials.gov with National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) as lead sponsor.

NCT NCT05440422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05440422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phase
Phase 2
Overall status
Recruiting
Start date
December 7, 2023
Completion date
August 2, 2027
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease, premature atherosclerosis, systemic lupus erythematosus